182 related articles for article (PubMed ID: 15596190)
21. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer.
Partin AW; Brawer MK; Subong EN; Kelley CA; Cox JL; Bruzek DJ; Pannek J; Meyer GE; Chan DW
Prostate Cancer Prostatic Dis; 1998 Jun; 1(4):197-203. PubMed ID: 12496895
[TBL] [Abstract][Full Text] [Related]
22. Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Jeong IG; Lee KH;
J Urol; 2008 Jan; 179(1):111-6. PubMed ID: 17997422
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
[TBL] [Abstract][Full Text] [Related]
24. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
[TBL] [Abstract][Full Text] [Related]
25. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
26. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Patel A
BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
[TBL] [Abstract][Full Text] [Related]
28. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
[TBL] [Abstract][Full Text] [Related]
29. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
30. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
31. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
[TBL] [Abstract][Full Text] [Related]
32. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
33. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
34. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
35. Effect of ejaculation on serum total and free prostate-specific antigen concentrations.
Herschman JD; Smith DS; Catalona WJ
Urology; 1997 Aug; 50(2):239-43. PubMed ID: 9255295
[TBL] [Abstract][Full Text] [Related]
36. Relationship between prostate size and percent free prostate-specific antigen in patients with operable prostate cancer.
Nativ O; Sabo E; Wald M; Halachmi S; Moskovitz B
Isr Med Assoc J; 2000 Dec; 2(12):889-91. PubMed ID: 11344767
[TBL] [Abstract][Full Text] [Related]
37. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
[TBL] [Abstract][Full Text] [Related]
38. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
39. Can percent free prostate-specific antigen reduce the need for prostate biopsy?
Lieberman S
Eff Clin Pract; 1999; 2(6):266-71. PubMed ID: 10788024
[TBL] [Abstract][Full Text] [Related]
40. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
